Literature DB >> 28730090

Critical pathway for primary open angle glaucoma diagnosis.

Alejandro R Allocco1, Julia A Ponce1, Maria J Riera1, Mauricio G Magurno1.   

Abstract

AIM: To develop a critical pathway for primary open angle glaucoma (POAG) diagnosis intended to be efficient, to unify criteria, reduce resource use and minimize costs to the health system.
METHODS: We performed a systematic search on PubMed, Cochrane, Embase and ClinicalTrials.org databases and classified the quality of evidence from level I through III.
RESULTS: A critical pathway was designed by setting a key-decision step by step model on the basis of the best current evidence.
CONCLUSION: A critical pathway, evidence-based guideline, may be a useful tool intended to reduce costs while maintaining or even improving the quality of care for diagnosing a highly prevalent pathology such as open angle glaucoma.

Entities:  

Keywords:  critical pathway; diagnosis; glaucoma; guideline

Year:  2017        PMID: 28730090      PMCID: PMC5515164          DOI: 10.18240/ijo.2017.06.21

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  37 in total

1.  Association between risk factors and glaucomatous damage in untreated primary open-angle glaucoma.

Authors:  Konstantin Gugleta; Anna Polunina; Asan Kochkorov; Nicolas Waldmann; Natalie Portmann; Robert Katamay; Josef Flammer; Selim Orgul
Journal:  J Glaucoma       Date:  2013-08       Impact factor: 2.503

2.  Lower corneal hysteresis is associated with more rapid glaucomatous visual field progression.

Authors:  Carlos V Gustavo De Moraes; Victoria Hill; Celso Tello; Jeffrey M Liebmann; Robert Ritch
Journal:  J Glaucoma       Date:  2012 Apr-May       Impact factor: 2.503

Review 3.  Myopia and glaucoma: sorting out the difference.

Authors:  Chi-Hsin Hsu; Rebecca I Chen; Shan C Lin
Journal:  Curr Opin Ophthalmol       Date:  2015-03       Impact factor: 3.761

4.  Type 2 diabetes mellitus and the risk of open-angle glaucoma the Los Angeles Latino Eye Study.

Authors:  Vikas Chopra; Rohit Varma; Brian A Francis; Joanne Wu; Mina Torres; Stanley P Azen
Journal:  Ophthalmology       Date:  2007-08-22       Impact factor: 12.079

5.  The number of people with glaucoma worldwide in 2010 and 2020.

Authors:  H A Quigley; A T Broman
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

6.  Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258

7.  Primary Open-Angle Glaucoma Preferred Practice Pattern(®) Guidelines.

Authors:  Bruce E Prum; Lisa F Rosenberg; Steven J Gedde; Steven L Mansberger; Joshua D Stein; Sayoko E Moroi; Leon W Herndon; Michele C Lim; Ruth D Williams
Journal:  Ophthalmology       Date:  2015-11-12       Impact factor: 12.079

8.  Spectral-Domain Optical Coherence Tomography for Glaucoma Diagnosis.

Authors:  Carolina P B Gracitelli; Ricardo Y Abe; Felipe A Medeiros
Journal:  Open Ophthalmol J       Date:  2015-05-15

Review 9.  Update on Normal Tension Glaucoma.

Authors:  Jyotiranjan Mallick; Lily Devi; Pradeep K Malik; Jogamaya Mallick
Journal:  J Ophthalmic Vis Res       Date:  2016 Apr-Jun

10.  Summary of Glaucoma Diagnostic Testing Accuracy: An Evidence-Based Meta-Analysis.

Authors:  Saad Ahmed; Zainab Khan; Francie Si; Alex Mao; Irene Pan; Fatemeh Yazdi; Alexander Tsertsvadze; Cindy Hutnik; David Moher; David Tingey; Graham E Trope; Karim F Damji; Jean-Eric Tarride; Ron Goeree; William Hodge
Journal:  J Clin Med Res       Date:  2016-07-30
View more
  1 in total

1.  Effects of topical low-dose preservative-free hydrocortisone on intraocular pressure in patients affected by ocular surface disease with and without glaucoma.

Authors:  M Filippelli; R dell'Omo; A Gelso; M Rinaldi; S Bartollino; P Napolitano; A Russo; G Campagna; C Costagliola
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-08-18       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.